NeoGenomics (NEO) Short Interest Ratio & Short Volume → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free NEO Stock Alerts $14.14 +0.29 (+2.09%) (As of 05:27 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media NeoGenomics Short Interest DataCurrent Short Volume7,640,000 sharesPrevious Short Volume7,240,000 sharesChange Vs. Previous Month+5.52%Dollar Volume Sold Short$105.05 millionShort Interest Ratio / Days to Cover8.5Last Record DateApril 15, 2024Outstanding Shares127,670,000 sharesPercentage of Shares Shorted5.98%Today's Trading Volume808,065 sharesAverage Trading Volume893,597 sharesToday's Volume Vs. Average90% Short Selling NeoGenomics ? Sign up to receive the latest short interest report for NeoGenomics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNEO Short Interest Over TimeNEO Days to Cover Over TimeNEO Percentage of Float Shorted Over Time Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. NeoGenomics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20247,640,000 shares $105.05 million +5.5%N/A8.5 $13.75 3/31/20247,240,000 shares $113.81 million -0.7%N/A7.9 $15.72 3/15/20247,290,000 shares $107.09 million +4.0%N/A7.1 $14.69 2/29/20247,010,000 shares $109.36 million -5.9%N/A6.2 $15.60 2/15/20247,450,000 shares $111.01 million -4.1%N/A6.7 $14.90 1/31/20247,770,000 shares $115.38 million -1.9%N/A7.4 $14.85 Get the Latest News and Ratings for NEO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20247,920,000 shares $125.29 million -14.8%N/A7.5 $15.82 12/31/20239,290,000 shares $150.31 million +2.4%N/A8.5 $16.18 12/15/20239,070,000 shares $178.32 million +18.7%N/A8.9 $19.66 11/30/20237,640,000 shares $138.82 million +21.7%N/A8.4 $18.17 11/15/20236,280,000 shares $110.90 million +2.1%N/A6.8 $17.66 10/31/20236,150,000 shares $86.22 million +25.5%N/A6.6 $14.02 10/15/20234,900,000 shares $61.25 million +2.1%N/A5.5 $12.50 9/30/20234,800,000 shares $59.04 million -19.5%N/A5.9 $12.30 9/15/20235,960,000 shares $80.22 million +9.0%N/A7.7 $13.46 8/31/20235,470,000 shares $82.21 million -5.9%N/A6.8 $15.03 8/15/20235,810,000 shares $78.55 million +1.4%N/A7.2 $13.52 7/31/20235,730,000 shares $99.30 million +1.2%N/A6.4 $17.33 7/15/20235,660,000 shares $97.69 million -2.8%N/A6.4 $17.26 6/30/20235,820,000 shares $93.53 million -11.0%N/A6.1 $16.07 6/15/20236,540,000 shares $106.21 million -14.7%N/A6.1 $16.24 5/31/20237,670,000 shares $131.77 million -3.0%N/A6.9 $17.18 5/15/20237,910,000 shares $151.32 million +11.7%N/A6.2 $19.13 4/30/20237,080,000 shares $103.51 million +12.7%N/A5.7 $14.62 4/15/20236,280,000 shares $96.21 million +7.7%N/A5.3 $15.32 3/31/20235,830,000 shares $101.50 million -10.2%N/A4.9 $17.41 3/15/20236,490,000 shares $120.78 million +26.5%N/A6.1 $18.61 2/28/20235,130,000 shares $86.44 million +15.0%N/A4.8 $16.85 2/15/20234,460,000 shares $60.57 million +4.0%N/A4.3 $13.58 1/31/20234,290,000 shares $50.97 million -3.2%N/A4.1 $11.88 1/15/20234,430,000 shares $48.64 million -1.3%N/A3.7 $10.98 12/30/20224,490,000 shares $41.49 million +27.9%N/A3.6 $9.24 12/15/20223,510,000 shares $38.05 million -30.6%N/A2.7 $10.84 11/30/20225,060,000 shares $56.72 million -17.1%N/A4 $11.21 11/15/20226,100,000 shares $68.69 million +9.5%N/A5 $11.26 10/31/20225,570,000 shares $42.39 million +3.3%N/A4.3 $7.61 10/15/20225,390,000 shares $38.00 million +32.1%N/A3.9 $7.05 9/30/20224,080,000 shares $35.13 million +2.0%N/A2.8 $8.61 9/15/20224,000,000 shares $42.24 million -5.2%N/A2.4 $10.56 8/31/20224,220,000 shares $42.41 million -9.6%N/A2.4 $10.05Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. NEO Short Interest - Frequently Asked Questions What is NeoGenomics' current short interest? Short interest is the volume of NeoGenomics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 7,640,000 shares of NEO short. Learn More on NeoGenomics' current short interest. What is a good short interest ratio for NeoGenomics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NEO shares currently have a short interest ratio of 8.0. Learn More on NeoGenomics's short interest ratio. Which institutional investors are shorting NeoGenomics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of NeoGenomics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is NeoGenomics' short interest increasing or decreasing? NeoGenomics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 7,640,000 shares, an increase of 5.5% from the previous total of 7,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does NeoGenomics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to NeoGenomics: Recursion Pharmaceuticals, Inc. (26.39%), Fusion Pharmaceuticals Inc. (5.73%), Twist Bioscience Co. (21.19%), Schrödinger, Inc. (8.88%), Agios Pharmaceuticals, Inc. (12.15%), Alphatec Holdings, Inc. (8.76%), Sana Biotechnology, Inc. (21.81%), Syndax Pharmaceuticals, Inc. (11.30%), Ginkgo Bioworks Holdings, Inc. (19.74%), Catalyst Pharmaceuticals, Inc. (6.18%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short NeoGenomics stock? Short selling NEO is an investing strategy that aims to generate trading profit from NeoGenomics as its price is falling. NEO shares are trading up $0.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NeoGenomics? A short squeeze for NeoGenomics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NEO, which in turn drives the price of the stock up even further. How often is NeoGenomics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NEO, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Recursion Pharmaceuticals Short Interest Fusion Pharmaceuticals Short Interest Twist Bioscience Short Interest Schrödinger Short Interest Agios Pharmaceuticals Short Interest Alphatec Short Interest Sana Biotechnology Short Interest Syndax Pharmaceuticals Short Interest Ginkgo Bioworks Short Interest Catalyst Pharmaceuticals Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NEO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press